uniQure announced June 17, 2026: FDA agreed that 3-year AMT-130 Phase I/II data supports an accelerated approval BLA for Huntington’s disease. BLA submission planned Q3 2026.
Recent Posts
- The U.S. Is Entering Summer’s Most Critical Blood Shortage — Here’s Why It Happens Every Year and What to Do About It Today
- The Sweetener Marketed to Diabetics May Be Silently Harming Their Livers. New Research from WashU Explains How.
- Colorectal Cancer Is Now the Leading Cancer Killer of Americans Under 50. The KFF Investigation Explains Why Family History Is More Important Than Ever.
- Huntington’s Disease Gene Therapy AMT-130 Is on Track for FDA Approval After uniQure Reaches Regulatory Agreement
- FDA Approves First Generic Baloxavir (Xofluza): Single-Dose Flu Treatment Now Available at Generic Price
Archives
- June 2026
- May 2026
- February 2026
- August 2025
- July 2025
- June 2025
- May 2025
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- February 2024
- January 2024
- December 2023
- September 2023
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
Recent Comments